⏱ News is delayed by 15 minutes. Sign in for real-time access.
Sign in
FATE News
Fate Therapeutics, Inc.
Cell-Based Therapies Poised to Disrupt Multi-Billion-Dollar Anti-Aging and Neurodegenerative Markets
prnewswire.com
LCTX
FATE
GERN
BIOA
Three TriKE Candidates In Clinic As NK Cell Engager Field Reorganizes
prnewswire.com
NKTX
GTBP
IBRX
FATE
INMB
Solid Tumor Treatment Race Heats Up as Multi-Billion-Dollar Oncology Market Enters High-Growth Phase
prnewswire.com
GTBP
ARTV
FATE
IBRX
CHRS
Form 8-K
sec.gov
FATE
Fate Therapeutics Reports First Quarter 2026 Financial Results and Business Updates
globenewswire.com
FATE
Fate Therapeutics Showcases FT819 Clinical Activity in SLE without the use of Conditioning Chemotherapy at the 2026 ASGCT Annual Meeting
globenewswire.com
FATE
Fate Therapeutics Selected for U.S. FDA Chemistry, Manufacturing, and Controls Development and Readiness Pilot Program to Support Manufacturing Readiness of FT819
globenewswire.com
FATE
Fate Therapeutics Announces Three Presentations at the 2026 ASGCT Annual Meeting Highlighting Off-the-Shelf CAR T-cell Therapy Pipeline for Cancer and Autoimmune Diseases
globenewswire.com
FATE
Fate Therapeutics Reports New Employee Inducement Award Under Nasdaq Listing Rule 5635(c)(4)
globenewswire.com
FATE
Fate Therapeutics Announces Data Presentation of FT819 Off-the-Shelf CAR T-Cell Product Candidate for Systemic Lupus Erythematosus (SLE) at the CCR – East 2026 Meeting
globenewswire.com
FATE